Developer docs
API playgroundTry for free, no card

Search company profiles

Angiolutions

Full company profile

uuid000amgv

Namestring
Angiolutions
Legal namestring
Angiolutions® GmbH
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Angiolutions GmbH is a privately held medical device company developing the A3-Shield® System, a first-in-class minimally invasive implant designed to halt the progression of early-stage abdominal aortic aneurysms (AAAs). The device acts as a mechanical shield that locally modulates and absorbs aortic pulse waves driving aneurysm growth, addressing the root cause of disease progression rather than the symptoms, and offering an active therapeutic option for the roughly 5% of the population affected by AAAs who currently face a 'watch and wait' surveillance paradigm with no approved intervention. The technology is protected by 16 filed patents across 5 patent families, with grants in both the US and EU, and is supported by an ISO 13485-certified quality management system.

The company is conducting the PRINCIPIIS-FIH first-in-human clinical trial, with the first patient treated in December 2025 at centers in Tashkent, Uzbekistan; additional trial sites include University Hospital Düsseldorf, Marienhospital Gelsenkirchen, and University Hospital Leipzig. The product consists of the A3-Shield® implant and its dedicated delivery system. The company is led by physician-founders and Co-CEOs Dr. Isabel N. Schellinger and Dr. Uwe Raaz, with Chief Business Officer Marius Rummel, supported by an interdisciplinary team and an Advisory Board and Medical Board of international vascular surgery and MedTech industry veterans.

Angiolutions is pre-revenue, with the A3-Shield® System classified as an investigational device not yet approved for commercial sale. Its business model is structured around future one-time device sales to hospitals and vascular surgery centers across the EU and US, pursued via direct enterprise field sales once regulatory approval is obtained. To date the company has been capitalized by a €2.5 million non-dilutive EIC Accelerator grant awarded in July 2023, with no institutional equity investors disclosed; the company is registered in Hannover, Germany.

Short descriptiontext

Angiolutions is a German medical device company developing the A3-Shield® System, a first-in-class minimally invasive implant that halts early-stage abdominal aortic aneurysm progression by absorbing aortic pulse waves. It targets vascular surgeons and hospitals serving AAA patients, and is currently in first-in-human clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDe Pere, United States
HQ citystring
De Pere
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
abdominal aortic aneurysm treatment, minimally invasive vascular implants, endovascular medical devices, pulse wave modulation therapy, cardiovascular implant innovation
Industry1 code
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Vascular Medical Devices
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeOne Time License
Description

Pre-revenue company. The A3-Shield® System is an investigational device currently in first-in-human clinical trials and not yet approved for commercial sale. Future revenue will come from direct sales of the implant to hospitals and vascular surgery centers.

angiolutions.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Angiolutions develops the A3-Shield® System, a first-in-class, minimally invasive implant designed to treat early-stage abdominal aortic aneurysms (AAAs) by locally modulating aortic pulse waves to halt aneurysm growth. The investigational device consists of the implant and its delivery system and addresses the root cause of AAA progression, an area with no active treatment options currently available. The product is currently in first-in-human clinical trials (PRINCIPIIS-FIH) and not yet approved for commercial sale.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • First patient successfully treated in December 2025 in PRINCIPIIS-FIH first-in-human clinical trial
Product overview1 text field

Angiolutions offers a single core product: the A3-Shield® System, which consists of the implant and its delivery system. This first-in-class medical device is designed to treat early-stage abdominal aortic aneurysms (AAAs) by locally modulating aortic pulse waves, addressing the root cause of aneurysm progression. The A3-Shield® System is currently an investigational device undergoing first-in-human clinical testing (PRINCIPIIS-FIH Trial) and is not approved for commercial sale.

Product and service1 record
1A3-Shield® System
CategoryVascular Medical Devices / Cardiovascular Implants
Description

First-of-its-kind medical implant system designed to treat early-stage abdominal aortic aneurysms (AAAs) by locally modulating aortic pulse waves to halt aneurysm growth. The system consists of the A3-Shield® implant and its minimally invasive delivery system, targeting the root cause of AAA progression. Intended for use by vascular surgeons and interventional cardiologists at hospitals and vascular surgery centers treating AAA patients.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2022-02-07
Description

DQS conducted the ISO 13485 certification audit for Angiolutions' fully digital quality management system. The audit was conducted thoroughly and efficiently, achieving certification within an ambitious schedule.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pure-play AAA device company with the AFX and Alto endovascular stent graft systems for AAA repair. Most directly comparable as a device-only company focused exclusively on abdominal aortic aneurysm treatment.

TypeBroad incumbent
Description

Major vascular MedTech incumbent with the Endurant AAA stent graft system. Operates broadly across vascular intervention but competes directly in the AAA treatment category where Angiolutions aims to introduce earlier-stage intervention.

3Cook Medical
TypeBroad incumbent
Description

Established AAA player with the Zenith Flex and Zenith Alpha endovascular graft lines. Large diversified medical device company with overlapping vascular surgery customer base and procedural workflows.

TypeBroad incumbent
Description

Developer of the Gore Excluder AAA stent graft and other vascular implants. Comparable as a long-standing AAA device innovator with deep vascular surgeon relationships and broad IP in endovascular devices.

TypeBroad incumbent
Description

Specialty division of Terumo focused on aortic stent grafts and surgical grafts (formerly Vascutek). Directly comparable in serving vascular surgeons treating aortic disease, including AAA.

TypeBroad incumbent
Description

Cardiovascular and vascular surgery company (formerly CryoLife) with aortic stent graft and surgical graft portfolio. Comparable as a vascular-focused incumbent serving similar vascular surgeon customers.

7MicroPort Scientific (Lombard Medical)
TypeDirect peer
Description

Acquired Lombard Medical, a pure-play AAA stent graft developer (Altura and iCAST). Comparable as a focused AAA device company whose customer base and clinical workflow overlap directly with Angiolutions' target users.

TypeEmerging player
Description

Vascular thrombectomy and embolization device company with growing presence in vascular surgery suites. Comparable as an innovative vascular MedTech expanding into new procedural indications served by similar clinicians.

TypeEmerging player
Description

Developer of intravascular lithotripsy (IVL) for calcified vascular disease. Comparable as a fast-growing vascular device innovator that introduced a novel mechanism of action into established vascular treatment categories.

TypeBroad incumbent
Description

Major vascular device division within Abbott with broad portfolio across coronary and peripheral intervention. Comparable as a scaled incumbent with overlapping interventional cardiology and vascular surgery customers and R&D capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Angiolutions

Vascular Medical Devicesangiolutions.com

Angiolutions is a German medical device company developing the A3-Shield® System, a first-in-class minimally invasive implant that halts early-stage abdominal aortic aneurysm progression by absorbing aortic pulse waves. It targets vascular surgeons and hospitals serving AAA patients, and is currently in first-in-human clinical trials.

What Angiolutions does

Angiolutions GmbH is a privately held medical device company developing the A3-Shield® System, a first-in-class minimally invasive implant designed to halt the progression of early-stage abdominal aortic aneurysms (AAAs). The device acts as a mechanical shield that locally modulates and absorbs aortic pulse waves driving aneurysm growth, addressing the root cause of disease progression rather than the symptoms, and offering an active therapeutic option for the roughly 5% of the population affected by AAAs who currently face a 'watch and wait' surveillance paradigm with no approved intervention. The technology is protected by 16 filed patents across 5 patent families, with grants in both the US and EU, and is supported by an ISO 13485-certified quality management system.

The company is conducting the PRINCIPIIS-FIH first-in-human clinical trial, with the first patient treated in December 2025 at centers in Tashkent, Uzbekistan; additional trial sites include University Hospital Düsseldorf, Marienhospital Gelsenkirchen, and University Hospital Leipzig. The product consists of the A3-Shield® implant and its dedicated delivery system. The company is led by physician-founders and Co-CEOs Dr. Isabel N. Schellinger and Dr. Uwe Raaz, with Chief Business Officer Marius Rummel, supported by an interdisciplinary team and an Advisory Board and Medical Board of international vascular surgery and MedTech industry veterans.

Angiolutions is pre-revenue, with the A3-Shield® System classified as an investigational device not yet approved for commercial sale. Its business model is structured around future one-time device sales to hospitals and vascular surgery centers across the EU and US, pursued via direct enterprise field sales once regulatory approval is obtained. To date the company has been capitalized by a €2.5 million non-dilutive EIC Accelerator grant awarded in July 2023, with no institutional equity investors disclosed; the company is registered in Hannover, Germany.

Angiolutions firmographics

Firmographics
Name
Angiolutions
Legal name
Angiolutions® GmbH
Website
https://angiolutions.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Angiolutions is a German medical device company developing the A3-Shield® System, a first-in-class minimally invasive implant that halts early-stage abdominal aortic aneurysm progression by absorbing aortic pulse waves. It targets vascular surgeons and hospitals serving AAA patients, and is currently in first-in-human clinical trials.
Ownership category
akta.pro rank

Angiolutions industry classification

Industry
Product category
Vascular Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Abdominal aortic aneurysm treatment
  • Minimally invasive vascular implants
  • Endovascular medical devices
  • Pulse wave modulation therapy
  • Cardiovascular implant innovation

Where Angiolutions is headquartered

Location

Headquarters

HQ city
De Pere
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Angiolutions business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Medical Device Sales: Pre-revenue company. The A3-Shield® System is an investigational device currently in first-in-human clinical trials and not yet approved for commercial sale. Future revenue will come from direct sales of the implant to hospitals and vascular surgery centers.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Angiolutions product offering

Product offering

Core offering

Angiolutions develops the A3-Shield® System, a first-in-class, minimally invasive implant designed to treat early-stage abdominal aortic aneurysms (AAAs) by locally modulating aortic pulse waves to halt aneurysm growth. The investigational device consists of the implant and its delivery system and addresses the root cause of AAA progression, an area with no active treatment options currently available. The product is currently in first-in-human clinical trials (PRINCIPIIS-FIH) and not yet approved for commercial sale.

Product overview

Angiolutions offers a single core product: the A3-Shield® System, which consists of the implant and its delivery system. This first-in-class medical device is designed to treat early-stage abdominal aortic aneurysms (AAAs) by locally modulating aortic pulse waves, addressing the root cause of aneurysm progression. The A3-Shield® System is currently an investigational device undergoing first-in-human clinical testing (PRINCIPIIS-FIH Trial) and is not approved for commercial sale.

Differentiator

Problem solved

Functional benefit

Products and services

  • A3-Shield® System First-of-its-kind medical implant system designed to treat early-stage abdominal aortic aneurysms (AAAs) by locally modulating aortic pulse waves to halt aneurysm growth. The system consists of the A3-Shield® implant and its minimally invasive delivery system, targeting the root cause of AAA progression. Intended for use by vascular surgeons and interventional cardiologists at hospitals and vascular surgery centers treating AAA patients.

Quantifiable outcome

  • First patient successfully treated in December 2025 in PRINCIPIIS-FIH first-in-human clinical trial

Companies that use Angiolutions

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Angiolutions technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Angiolutions partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Angiolutions competitors and assessment

Company assessment

Direct peers

  • Endologix: Pure-play AAA device company with the AFX and Alto endovascular stent graft systems for AAA repair. Most directly comparable as a device-only company focused exclusively on abdominal aortic aneurysm treatment.
  • MicroPort Scientific (Lombard Medical): Acquired Lombard Medical, a pure-play AAA stent graft developer (Altura and iCAST). Comparable as a focused AAA device company whose customer base and clinical workflow overlap directly with Angiolutions' target users.

Broad incumbents

  • Medtronic: Major vascular MedTech incumbent with the Endurant AAA stent graft system. Operates broadly across vascular intervention but competes directly in the AAA treatment category where Angiolutions aims to introduce earlier-stage intervention.
  • Cook Medical: Established AAA player with the Zenith Flex and Zenith Alpha endovascular graft lines. Large diversified medical device company with overlapping vascular surgery customer base and procedural workflows.
  • W. L. Gore & Associates: Developer of the Gore Excluder AAA stent graft and other vascular implants. Comparable as a long-standing AAA device innovator with deep vascular surgeon relationships and broad IP in endovascular devices.
  • Terumo Aortic: Specialty division of Terumo focused on aortic stent grafts and surgical grafts (formerly Vascutek). Directly comparable in serving vascular surgeons treating aortic disease, including AAA.
  • Artivion: Cardiovascular and vascular surgery company (formerly CryoLife) with aortic stent graft and surgical graft portfolio. Comparable as a vascular-focused incumbent serving similar vascular surgeon customers.
  • Abbott Vascular: Major vascular device division within Abbott with broad portfolio across coronary and peripheral intervention. Comparable as a scaled incumbent with overlapping interventional cardiology and vascular surgery customers and R&D capabilities.

Emerging players

  • Penumbra: Vascular thrombectomy and embolization device company with growing presence in vascular surgery suites. Comparable as an innovative vascular MedTech expanding into new procedural indications served by similar clinicians.
  • Shockwave Medical: Developer of intravascular lithotripsy (IVL) for calcified vascular disease. Comparable as a fast-growing vascular device innovator that introduced a novel mechanism of action into established vascular treatment categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Angiolutions social profiles

Digital presence

Angiolutions compliance and trust

Trust signal

Compliance1 record

Angiolutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Angiolutions leadership team

Management profile

Number of profiles

Profiles6 records

Angiolutions funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Angiolutions M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Angiolutions

What does Angiolutions do?

Angiolutions develops the A3-Shield® System, a first-in-class, minimally invasive implant designed to treat early-stage abdominal aortic aneurysms (AAAs) by locally modulating aortic pulse waves to halt aneurysm growth. The investigational device consists of the implant and its delivery system and addresses the root cause of AAA progression, an area with no active treatment options currently available. The product is currently in first-in-human clinical trials (PRINCIPIIS-FIH) and not yet approved for commercial sale.

Is Angiolutions a public or private company?

Angiolutions is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Angiolutions founded?

Angiolutions was founded in 2020. It employs 1 to 10 people.

Where is Angiolutions based?

Angiolutions is headquartered in De Pere, United States, in the North America region.

How does Angiolutions make money?

One revenue line is on record: medical Device Sales.

Who are Angiolutions's main competitors?

Direct peers on record are Endologix and MicroPort Scientific (Lombard Medical). Broad incumbents are Medtronic, Cook Medical, W. L. Gore & Associates, Terumo Aortic, Artivion and Abbott Vascular. Emerging players are Penumbra and Shockwave Medical.

Does Angiolutions have an API?

No public API is recorded for Angiolutions.

What industry is Angiolutions in?

Angiolutions's product category is Vascular Medical Devices. Its primary akta.pro industry code is HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales